“Product” means a therapeutic or diagnostic product or treatment regimen utilizing (a) the Seller Therapy as a monotherapy, (b) the Seller Therapy in a treatment for human patients comprised of concurrent or sequential administration of the Seller Therapy and one or more of the following approved or additional therapies (any such Product, a “Combination Therapy”): chemotherapies, radiation, cytokines, vaccines, antibodies, immunotherapies, and/or other pharmaceutical or biological agents, or (c) the Betabody Technology in or as a diagnostic.
Transferred Assets. Upon the terms and subject to the conditions of this Agreement, Seller hereby sells, assigns, conveys and delivers to Buyer all of Seller’s rights, title and interests in, to and under, the following assets rights and properties (collectively with the License Agreements, and Seller’s interest in the jointly owned patents, unpublished patent applications and trademarks referred to under Section 2.2, the “Transferred Assets”): (a) Seller’s entire inventory of bavituximab, as set forth on the drug product and supply inventory list attached hereto as Schedule 2.3(a); (b) to the extent in Seller’s possession or control, all cell banks (including master cell banks, research cell banks, and working cell banks) with respect to bavituximab, 3G4, 2aG4 and mch1N11, as set forth on the cell bank inventory list attached hereto as Schedule 2.3(b); (c) manufacturing instructions for bavituximab, in the form described in Section 5.2(d); (d) all Development Data, and preclinical, clinical data and all Regulatory Documentation under all UTSW License Agreements in Seller’s possession; (e) the US Adopted Names Council nonproprietary drug name “bavituximab”; (f) all of Seller’s right, title and interest in and to Seller’s inventory of those certain Betabody molecules and cell lines developed by Seller (the “Betabody Cell Lines”); 6 (g) proprietary assay for Beta2Glycoprotein1-Bavituximab Interaction; (h) know-how, including protocol(s) with respect to all quality release assays for the manufacture of bavituximab, to the extent owned by, or in the possession or control of Seller; (i) clinical trial biospecimens of interest, subject to and in accordance with Section 7.6, below; (j) that certain antibody known as 24MC1N11 or PGN635 or 1N11 (hereafter, “1N11”); and (k) that certain antibody known as 11.31, jointly owned by Seller and Affitech Research AS.
Market Data 
Markets 
AI
